Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects

Background: Growth hormone-releasing peptides (GHRPs) constitute a group of small synthetic peptides that stimulate the growth hormone secretion and the downstream axis activity. Mounting evidences since the early 1980s delineated unexpected pharmacological cardioprotective and cytoprotective properties for the GHRPs. However, despite intense basic pharmacological research, alternatives to prevent cell and tissue demise before lethal insults have remained as an empty niche in the clinical armamentarium. Here, we have rigorously reviewed the investigational development of GHRPs and their clinical niching perspectives. Methodology: PubMed/MEDLINE databases, including original research and review articles, were explored. The search design was date escalated from 1980 and included articles in English only. Results and Conclusions: GHRPs bind to two different receptors (GHS-R1a and CD36), which redundantly or independently exert relevant biological effects. GHRPs’ binding to CD36 activates prosurvival pathways such as PI-3K/AKT1, thus reducing cellular death. Furthermore, GHRPs decrease reactive oxygen species (ROS) spillover, enhance the antioxidant defenses, and reduce inflammation. These cytoprotective abilities have been revealed in cardiac, neuronal, gastrointestinal, and hepatic cells, representing a comprehensive spectrum of protection of parenchymal organs. Antifibrotic effects have been attributed to some of the GHRPs by counteracting fibrogenic cytokines. In addition, GHRP family members have shown a potent myotropic effect by promoting anabolia and inhibiting catabolia. Finally, GHRPs exhibit a broad safety profile in preclinical and clinical settings. Despite these fragmented lines incite to envision multiple pharmacological uses for GHRPs, especially as a myocardial reperfusion damage-attenuating candidate, this family of “drugable” peptides awaits for a definitive clinical niche.

[1]  Jorge Berlanga Acosta,et al.  Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds , 2016, Plastic surgery international.

[2]  C. Gibson,et al.  Assessment of dose–effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy , 2016, Neurological research.

[3]  Bong-Woo Kim,et al.  Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I , 2015, BMB reports.

[4]  Alan R. Harvey,et al.  The Acquisition of Target Dependence by Developing Rat Retinal Ganglion Cells , 2015, eNeuro.

[5]  A. Abizaid,et al.  Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target1,2,3 , 2015, eNeuro.

[6]  Zhen Zhang,et al.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases , 2015, Endocrine.

[7]  Yuanfeng Xia,et al.  Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile , 2014, Journal of cachexia, sarcopenia and muscle.

[8]  T. Tokudome,et al.  The cardiovascular action of hexarelin , 2014, Journal of geriatric cardiology : JGC.

[9]  P. Saura,et al.  Seguridad clínica del péptido liberador de la hormona de crecimiento-6 (GHRP-6) en voluntarios sanos , 2014 .

[10]  P. Simkhada,et al.  Cardioprotective Effects of Ghrelin in Heart Failure: From Gut to Heart , 2014, Heart views : the official journal of the Gulf Heart Association.

[11]  Jorge Amador Berlanga Acosta,et al.  Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats , 2014 .

[12]  H. Szeto First‐in‐class cardiolipin‐protective compound as a therapeutic agent to restore mitochondrial bioenergetics , 2014, British journal of pharmacology.

[13]  P. Loria,et al.  Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. , 2014, ACS medicinal chemistry letters.

[14]  N. Minamino,et al.  Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. , 2013, Endocrinology.

[15]  Shiqiang Yu,et al.  Cardioprotective Effect of Ghrelin in Cardiopulmonary Bypass Involves a Reduction in Inflammatory Response , 2013, PloS one.

[16]  E. Braunwald Cardiovascular science: opportunities for translating research into improved care. , 2013, The Journal of clinical investigation.

[17]  Ji-min Cao,et al.  Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. , 2012, American journal of physiology. Heart and circulatory physiology.

[18]  B. Launikonis,et al.  Growth hormone secretagogues preserve the electrophysiological properties of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart. , 2012, Endocrinology.

[19]  Ji-min Cao,et al.  Gastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6. , 2012, World journal of gastroenterology.

[20]  M. Ochagavía,et al.  Growth Hormone Releasing Peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats , 2012 .

[21]  B. Launikonis,et al.  Growth Hormone Secretagogues Protect Mouse Cardiomyocytes from in vitro Ischemia/Reperfusion Injury through Regulation of Intracellular Calcium , 2012, PloS one.

[22]  E. Braunwald Clinical Efforts to Reduce Myocardial Infarct Size—The Next Step , 2011, Journal of cardiovascular pharmacology and therapeutics.

[23]  W. Zang,et al.  Effects of GH secretagogues on contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes. , 2010, Endocrinology.

[24]  Chao-shu Tang,et al.  Ghrelin and Cardiovascular Diseases , 2009, Current Cardiology Reviews.

[25]  P. Delafontaine,et al.  Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. , 2009, Endocrinology.

[26]  A. Asakawa,et al.  Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. , 2008, World journal of gastroenterology.

[27]  K. Chihara,et al.  GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. , 2008, Life sciences.

[28]  S. Grottoli,et al.  Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood , 2007, Pituitary.

[29]  A. Rodrigue-Way,et al.  A growth hormone-releasing peptide promotes mitochondrial biogenesis and a fat burning-like phenotype through scavenger receptor CD36 in white adipocytes. , 2007, Endocrinology.

[30]  J. S. Alba,et al.  Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. , 2007, Clinical science.

[31]  R. Playford,et al.  Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. , 2006, Clinical science.

[32]  M. Granado,et al.  Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. , 2005, American journal of physiology. Endocrinology and metabolism.

[33]  R. Silverstein,et al.  Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. , 2004, The Biochemical journal.

[34]  R. Bolli,et al.  Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy , 2004, Circulation research.

[35]  Ji-min Cao,et al.  The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart. , 2003, Endocrinology.

[36]  R. Hargreaves,et al.  A Growth Hormone Secretagogue Prevents Ischemic-Induced Mortality Independently of the Growth Hormone Pathway in Dogs with Chronic Dilated Cardiomyopathy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[37]  C. Ohlsson,et al.  Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. , 2002, The Journal of endocrinology.

[38]  E. Ghigo,et al.  Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. , 2002, European journal of pharmacology.

[39]  R. Silverstein,et al.  CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart , 2002, Circulation research.

[40]  M. Root,et al.  Clinical pharmacology of human growth hormone and its secretagogues. , 2002, Current drug targets. Immune, endocrine and metabolic disorders.

[41]  E. Arvat,et al.  Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy , 2001, Endocrine.

[42]  M. Papotti,et al.  Growth hormone-releasing peptides and the cardiovascular system. , 2000, Annales d'endocrinologie.

[43]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[44]  E. Ghigo,et al.  Cardiac effects of hexarelin in hypopituitary adults. , 1999, European journal of pharmacology.

[45]  M. Morello,et al.  Activity of GH/IGF‐I axis in patients with dilated cardiomyopathy , 1999, Journal of endocrinological investigation.

[46]  C. Bowers,et al.  Growth hormone-releasing peptide (GHRP) , 1998, Cellular and Molecular Life Sciences CMLS.

[47]  M. Bernareggi,et al.  Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. , 1998, Journal of cardiovascular pharmacology.

[48]  M. Bernareggi,et al.  Cardiac ischemia and impairment of vascular endothelium function in hearts from GH-deficient rats: Protection by hexarelin , 1997 .

[49]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[50]  Diana García del Barco Herrera,et al.  Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats. , 2014, Iranian journal of kidney diseases.

[51]  Jorge Amador Berlanga Acosta,et al.  Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke. , 2013, Restorative neurology and neuroscience.

[52]  L. Silengo,et al.  Cardiotropic effect of GHRP-6 : in vivo characterization by echocardiography , 2013 .

[53]  T. Tokudome,et al.  Ghrelin and cardiovascular diseases. , 2012, Journal of cardiology.

[54]  E. Montero,et al.  Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis. , 2011, Restorative neurology and neuroscience.

[55]  K. Nagata,et al.  Beneficial effects of growth hormone-releasing peptide on myocardial oxidative stress and left ventricular dysfunction in dilated cardiomyopathic hamsters. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[56]  D. Cibrian,et al.  Therapeutic Effect of the Combined Use of Growth Hormone Releasing Peptide-6 and Epidermal Growth Factor in an Axonopathy Model , 2010, Neurotoxicity Research.

[57]  M. Granado,et al.  GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. , 2008, American journal of physiology. Endocrinology and metabolism.

[58]  J. Suárez,et al.  Efecto citoprotector cardíaco y extracardíaco del péptido GHRP6 , 2008 .

[59]  D. Lamontagne,et al.  Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. , 2006, Cardiovascular research.

[60]  H. Izawa,et al.  Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters. , 2004, Cardiovascular research.

[61]  E. Arvat,et al.  Natural and Synthetic Growth Hormone Secretagogues , 2003, Treatments in endocrinology.

[62]  G. Van den Berghe,et al.  Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. , 2000, Endocrinology.

[63]  M. Bernareggi,et al.  Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. , 1997, European journal of pharmacology.

[64]  M. Bernareggi,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Growth Hormone-Independent Cardioprotective Effects of Hexarelin in the Rat* , 2022 .